Health Catalyst (NASDAQ:HCAT) Given New $5.00 Price Target at Stephens

Health Catalyst (NASDAQ:HCAT - Get Free Report) had its target price cut by research analysts at Stephens from $7.00 to $5.00 in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage presently has an "equal weight" rating on the stock. Stephens' price objective would suggest a potential upside of 25.94% from the company's previous close.

A number of other analysts have also recently commented on HCAT. Piper Sandler reduced their target price on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a report on Tuesday, February 11th. Royal Bank of Canada reduced their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Thursday, February 27th. Stifel Nicolaus dropped their price objective on Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday, February 27th. Citigroup reduced their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Finally, Wells Fargo & Company cut their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $9.27.

Remove Ads

Health Catalyst Stock Performance

Shares of HCAT traded down $0.32 during trading hours on Thursday, hitting $3.97. The stock had a trading volume of 1,010,415 shares, compared to its average volume of 898,574. The firm has a market capitalization of $278.74 million, a PE ratio of -2.94 and a beta of 1.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 12 month low of $3.76 and a 12 month high of $9.24. The stock has a fifty day moving average price of $5.73 and a 200 day moving average price of $7.16.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the sale, the chief operating officer now directly owns 216,250 shares in the company, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,972 shares of company stock worth $412,930 in the last 90 days. Corporate insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HCAT. Quantbot Technologies LP purchased a new position in shares of Health Catalyst in the 4th quarter valued at $29,000. Quest Partners LLC bought a new position in Health Catalyst in the 3rd quarter worth about $34,000. Group One Trading LLC raised its stake in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after purchasing an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC bought a new position in Health Catalyst during the 4th quarter valued at $63,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Health Catalyst in the 3rd quarter worth approximately $84,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.